JP2014508753A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014508753A5 JP2014508753A5 JP2013553947A JP2013553947A JP2014508753A5 JP 2014508753 A5 JP2014508753 A5 JP 2014508753A5 JP 2013553947 A JP2013553947 A JP 2013553947A JP 2013553947 A JP2013553947 A JP 2013553947A JP 2014508753 A5 JP2014508753 A5 JP 2014508753A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- group
- compound
- hydrogen
- anemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000000547 substituted alkyl group Chemical group 0.000 claims 12
- 208000007502 anemia Diseases 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 6
- 125000003107 substituted aryl group Chemical group 0.000 claims 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 4
- 125000002252 acyl group Chemical group 0.000 claims 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000016286 Iron metabolism disease Diseases 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022971 Iron Deficiencies Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010062237 Renal impairment Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 230000005986 heart dysfunction Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 230000005977 kidney dysfunction Effects 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11155103 | 2011-02-18 | ||
| EP11155103.2 | 2011-02-18 | ||
| US201161473223P | 2011-04-08 | 2011-04-08 | |
| US61/473,223 | 2011-04-08 | ||
| US13/364,566 | 2012-02-02 | ||
| US13/364,566 US20120214803A1 (en) | 2011-02-18 | 2012-02-02 | Novel Sulfonaminoquinoline Hepcidin Antagonists |
| PCT/EP2012/052694 WO2012110603A1 (en) | 2011-02-18 | 2012-02-16 | Novel sulfonaminoquinoline hepcidin antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014508753A JP2014508753A (ja) | 2014-04-10 |
| JP2014508753A5 true JP2014508753A5 (https=) | 2015-03-05 |
| JP5948352B2 JP5948352B2 (ja) | 2016-07-06 |
Family
ID=44201356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553947A Expired - Fee Related JP5948352B2 (ja) | 2011-02-18 | 2012-02-16 | 新規なスルホンアミノキノリン系ヘプシジン拮抗薬 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20120214803A1 (https=) |
| EP (1) | EP2675526B1 (https=) |
| JP (1) | JP5948352B2 (https=) |
| KR (1) | KR20140009396A (https=) |
| CN (1) | CN103492028B (https=) |
| AR (1) | AR085283A1 (https=) |
| AU (1) | AU2012217021A1 (https=) |
| BR (1) | BR112013020916A2 (https=) |
| CA (1) | CA2826463A1 (https=) |
| ES (1) | ES2623229T3 (https=) |
| MX (1) | MX2013009522A (https=) |
| RU (1) | RU2013142448A (https=) |
| TW (1) | TW201302710A (https=) |
| WO (1) | WO2012110603A1 (https=) |
| ZA (1) | ZA201306005B (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012122534A2 (en) | 2011-03-10 | 2012-09-13 | The Trustees Of Columbia University In The City Of New York | N-quinolin-benzensulfonamides and related compounds for the treatment of cancer, autoimmune disorders and inflammation |
| EP2956138B1 (en) | 2013-02-15 | 2022-06-22 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| MX368903B (es) | 2013-02-20 | 2019-10-21 | Kala Pharmaceuticals Inc | Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas. |
| WO2014133059A1 (ja) | 2013-02-28 | 2014-09-04 | 武田薬品工業株式会社 | スルホニルクロライド化合物の製造法 |
| SG10202103278TA (en) | 2013-10-14 | 2021-04-29 | Eisai R&D Man Co Ltd | Selectively substituted quinoline compounds |
| ES2670550T3 (es) | 2013-10-14 | 2018-05-30 | Eisai R&D Management Co., Ltd. | Derivados de quinolina selectivamente sustituidos |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US9458169B2 (en) | 2013-11-01 | 2016-10-04 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| WO2016025779A1 (en) * | 2014-08-14 | 2016-02-18 | Rigel Pharmaceuticals, Inc. | Quinoline derivatives useful as ubiquitination inhibitors |
| CN105237476A (zh) * | 2015-10-31 | 2016-01-13 | 高大元 | 一种4-氯-8-氨基喹啉的合成方法 |
| PT3889145T (pt) * | 2015-12-17 | 2024-04-02 | Merck Patent Gmbh | 8-ciano-5-piperidino-quinolinas como antagonistas de tlr7/8 e suas utilizações para tratamento de distúrbios imunitários |
| EP4198031A1 (en) | 2016-08-08 | 2023-06-21 | Merck Patent GmbH | Tlr7/8 antagonists and uses thereof |
| AU2017324713B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3509423A4 (en) | 2016-09-08 | 2020-05-13 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
| US10336767B2 (en) | 2016-09-08 | 2019-07-02 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| FI3728194T3 (fi) * | 2017-12-20 | 2025-09-08 | Otago Innovation Ltd | Kinoliinisulfonamidiyhdisteitä ja niiden käyttö antibakteerisina aineina |
| CN111253934B (zh) * | 2018-11-30 | 2023-06-16 | 中国科学院大连化学物理研究所 | 一种双光子荧光探针及其制备和应用 |
| CN110407721A (zh) * | 2019-08-13 | 2019-11-05 | 上海毕得医药科技有限公司 | 一种4-氰基-3-(三氟甲基)苯-1-磺酰氯的合成方法 |
| US20220372135A1 (en) | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| US12508262B2 (en) | 2020-04-30 | 2025-12-30 | Keros Therapeutics, Inc. | Methods of using ALK2 inhibitors |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| EP4291555A1 (en) * | 2021-02-09 | 2023-12-20 | Celgene Corporation | Sulfonamides and their use for treatment of helminthic infections and diseases |
| IT202100013244A1 (it) | 2021-05-21 | 2022-11-21 | Fond Telethon | MODULATORI DI PrPC E LORO USI |
| CN113292490B (zh) * | 2021-06-04 | 2022-05-10 | 石家庄学院 | 一种识别氯离子的荧光探针及其制备方法和用途 |
| CN113717080A (zh) * | 2021-10-09 | 2021-11-30 | 西安瑞联新材料股份有限公司 | 一种4-氯-2-氰基苯磺酰氯的合成方法 |
| US20240294548A1 (en) * | 2021-10-12 | 2024-09-05 | Peloton Therapeutics Inc. | Tricyclic sultams and sulfamides as antitumor agents |
| CN120514715B (zh) * | 2025-07-25 | 2025-10-17 | 深圳国家感染性疾病临床医学研究中心 | 磺胺类化合物的应用、结核分枝杆菌抑制剂、药物组合物及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1025618C (zh) * | 1988-12-26 | 1994-08-10 | 日高弘义 | 异喹啉磺酰胺衍生物的制备方法 |
| US5627193A (en) | 1995-02-09 | 1997-05-06 | Mitsui Toatsu Chemicals, Inc. | Quinoline-4-carbonylguanidine derivatives, process for producing the same and pharmaceutical preparations containing the compounds |
| US7166448B1 (en) | 1999-05-10 | 2007-01-23 | Children's Medical Center Corproation | Ferroportin1 nucleic acids and proteins |
| EP1392345B2 (en) | 2001-05-25 | 2018-02-28 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis |
| RU2359268C2 (ru) | 2002-11-19 | 2009-06-20 | ДиАрДжи ИНТЕРНЭШНЛ, ИНК. | Способ диагностики заболеваний путем скрининга тканей, крови или жидкостей организма животных или человека на предмет обнаружения нефизиологических уровней гепсидина и его терапевтическое применение |
| US8614204B2 (en) * | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| US7723063B2 (en) | 2004-04-28 | 2010-05-25 | Intrinsic Lifesciences | Methods for measuring levels of bioactive human hepcidin |
| CA2549477A1 (en) | 2005-06-29 | 2006-12-29 | The Regents Of The University Of California | Competitive regulation of hepcidin mrna by soluble and cell-associated hemojuvelin |
| US20070254894A1 (en) | 2006-01-10 | 2007-11-01 | Kane John L Jr | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation |
| EP2066687A4 (en) | 2006-09-21 | 2010-12-08 | Alnylam Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HAMP GENE |
| WO2008074068A1 (en) * | 2006-12-20 | 2008-06-26 | Prana Biotechnology Limited | Substituted quinoline derivatives as antiamyloidogeneic agents |
| TW201307390A (zh) | 2007-02-02 | 2013-02-16 | Amgen Inc | 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法 |
| AR065628A1 (es) | 2007-03-07 | 2009-06-17 | Xenon Pharmaceuticals Inc | Compuestos triciclicos de utilidad en el tratamiento de trastornos por carencia de hierro en el organismo |
| AR065785A1 (es) | 2007-03-19 | 2009-07-01 | Xenon Pharmaceuticals Inc | Compuestos biarilo y biheteroarilo de utilidad en el tratamiento de trastornos de hierro |
| WO2008121861A2 (en) | 2007-03-28 | 2008-10-09 | Xenon Pharmaceuticals Inc. | Pyrazole and pyrrole compounds useful in treating iron disorders |
| US20100093611A1 (en) | 2007-05-16 | 2010-04-15 | Horrigan Stephen K | Compounds and methods for treating or preventing autoimmune diseases |
| WO2008151288A2 (en) | 2007-06-05 | 2008-12-11 | Xenon Pharmaceuticals Inc. | Aromatic and heteroaromatic compounds useful in treating iron disorders |
| GR1006896B (el) | 2007-08-24 | 2010-07-20 | Ελληνικο Ινστιτουτο Παστερ, | Μεθοδος παραγωγης μιας πεπτιδικης ορμονης |
| ATE553778T1 (de) | 2007-10-02 | 2012-05-15 | Inst Nat Sante Rech Med | Für humanes hepcidin spezifische antikörper |
| AR069062A1 (es) | 2007-11-02 | 2009-12-23 | Lilly Co Eli | Anticuerpo anti-hepcidina |
| ES2586459T3 (es) | 2008-05-01 | 2016-10-14 | Glaxosmithkline Llc | Quinolinas y análogos relacionados como moduladores de sirtuina |
| WO2010051064A1 (en) | 2008-10-30 | 2010-05-06 | The Trustees Of Columbia University In The City Of New York | COMPOUNDS THAT INHIBIT NFκB ACTIVITY |
-
2012
- 2012-02-02 US US13/364,566 patent/US20120214803A1/en not_active Abandoned
- 2012-02-16 AU AU2012217021A patent/AU2012217021A1/en not_active Abandoned
- 2012-02-16 BR BR112013020916A patent/BR112013020916A2/pt not_active IP Right Cessation
- 2012-02-16 JP JP2013553947A patent/JP5948352B2/ja not_active Expired - Fee Related
- 2012-02-16 WO PCT/EP2012/052694 patent/WO2012110603A1/en not_active Ceased
- 2012-02-16 CN CN201280018909.9A patent/CN103492028B/zh not_active Expired - Fee Related
- 2012-02-16 ES ES12704090.5T patent/ES2623229T3/es active Active
- 2012-02-16 RU RU2013142448/04A patent/RU2013142448A/ru unknown
- 2012-02-16 CA CA2826463A patent/CA2826463A1/en not_active Abandoned
- 2012-02-16 EP EP12704090.5A patent/EP2675526B1/en not_active Not-in-force
- 2012-02-16 MX MX2013009522A patent/MX2013009522A/es not_active Application Discontinuation
- 2012-02-16 KR KR1020137025002A patent/KR20140009396A/ko not_active Withdrawn
- 2012-02-17 TW TW101105292A patent/TW201302710A/zh unknown
- 2012-02-17 AR ARP120100551A patent/AR085283A1/es not_active Application Discontinuation
-
2013
- 2013-08-08 ZA ZA2013/06005A patent/ZA201306005B/en unknown
-
2014
- 2014-06-20 US US14/310,254 patent/US9102688B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014508753A5 (https=) | ||
| RU2013142448A (ru) | Новые сульфонаминохинолиновые антагонисты гепсидина | |
| JP2012092103A5 (https=) | ||
| JP2013510120A5 (https=) | ||
| JP2013540713A5 (https=) | ||
| JP2013032389A5 (https=) | ||
| JP2016503793A5 (https=) | ||
| JP2012144574A5 (https=) | ||
| JP2016503797A5 (https=) | ||
| EP3440090A4 (en) | RNA LIGAND-DISPLAYING EXOSOMES FOR THE SPECIFIC DELIVERY OF THERAPEUTICS IN CELLS BY RNA NANOTECHNOLOGY | |
| JP2012092123A5 (https=) | ||
| JP2011168603A5 (https=) | ||
| WO2015081133A3 (en) | Nucleotides for the treatment of liver cancer | |
| JP2013542261A5 (https=) | ||
| JP2013518107A5 (https=) | ||
| JP2013542247A5 (https=) | ||
| JP2014511891A5 (https=) | ||
| JP2014508811A5 (https=) | ||
| JP2018531941A5 (https=) | ||
| JP2011105738A5 (https=) | ||
| JP2012524055A5 (https=) | ||
| JP2015504067A5 (https=) | ||
| JP2014500861A5 (https=) | ||
| JP2014510729A5 (https=) | ||
| EP2558466A4 (en) | PHOSPHONATES WITH REDUCED TOXICITY FOR THE TREATMENT OF VIRUS INFECTIONS |